Frontier Pharma : Pain Treatment Teeming Market
Big Pharma companies such as Novartis, Boehringer Ingelheim, Sanofi, Allergan, and Merck & Co. are reportedly driving the pain treatment and therapeutics market in the segment of innovation. Merck led the market between 2008 in terms of patent grants, with 59 out of 142 patent applications being granted. Boehringer Ingelheim was granted 35, Allergan received 34, while Novartis and Sanofi received 30 each. The pain treatment and management market is largely fragmented and this poses an opportunity for new classes of drugs as numerous blockbuster patents near expiration. Table of Contents 1 Table of Contents 1.1 List of Figures 2 Executive Summary 2.1 Large and Innovative Pipeline 2.2 Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents 2.3 Active Deals landscape with Numerous Investment Oppertunities 3 The Case for Innovation 3.1 Growing Opportunities for Biologic Products 3.2 Diversification of Molecular Targets 3.3 Innovative First-in-Class Product Development Remains Attractive 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 3.5 Sustained Innovation 3.6 MRRSE Research Report Guidance 4 Clinical and Commercial Landscape 4.1 Disease Overview 4.1.1 Chronic and Neuropathic Pain 4.1.2 Disease Pathophysiology 4.1.3 Diagnosis 4.1.4 Treatment Option 4.1.5 Treatment Algorithm
4.2 Overview of Marketed Products for Pain 4.2.1 Analgesic Product Categories 4.2.2 Molecular Type Analysis 4.2.3 Molecular Target Analysis 4.2.4 Current Unmet Needs Send An Enquiry : http://www.mrrse.com/enquiry/108 5 Assessment of Pipeline Product Innovation 5.1 Pain Pipeline by Molecule Type, Phase and Therapeutic Targets 5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family 5.3 First-in-Class Pipeline Programs 5.4 First-in-Class Targets by Pain Subtype 6 Pain Patent Analysis 7 First-in-Class Target and Pipeline Program Evaluation 7.1 Pipeline Programs Targeting Fatty Acid Amide Hydrolase 7.2 Pipeline Programs Targeting Purinoceptor 3 7.3 Pipeline Programs Targeting Purinoceptor 7 7.4 Pipeline Programs Targeting Purinoceptor 4 7.5 Pipeline Programs Targeting Orexin Receptor Type 1 7.6 Pipeline Programs Targeting Neuronal Nitric Oxide Synthase 7.7 Pipeline Programs that Target Tropomyosin-Related Kinase A 7.8 Pipeline Programs that Target C-C Chemokine Receptor 2 7.9 Pipeline Programs that Target Endomorphin 2 7.10 Pipeline Programs that Target Protein Kinase C? 7.11 Pipeline Programs that Target Opioid Receptor-Like-1 Receptor 7.12 Pipeline Programs that Target Bradykinin B1 Receptor 7.13 Pipeline Programs Targeting Galanin Receptor 2 7.14 Pipeline Programs Targeting Nerve Growth Factor
- Page 1: Frontier Pharma : Pain Treatment Te
- Page 5 and 6: Phosphate Minerals Market - Global
Big <strong>Pharma</strong> companies such as Novartis, Boehringer Ingelheim, Sanofi, Allergan, and Merck & Co.<br />
are reportedly driving the pain treatment and therapeutics market in the segment of innovation.<br />
Merck led the market between 2008 in terms of patent grants, with 59 out of 142 patent<br />
applications being granted. Boehringer Ingelheim was granted 35, Allergan received 34, while<br />
Novartis and Sanofi received 30 each.<br />
The pain treatment and management market is largely fragmented and this poses an opportunity<br />
for new classes of drugs as numerous blockbuster patents near expiration.<br />
Table of Contents<br />
1 Table of Contents<br />
1.1 List of Figures<br />
2 Executive Summary<br />
2.1 Large and Innovative Pipeline<br />
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents<br />
2.3 Active Deals landscape with Numerous Investment Oppertunities<br />
3 The Case for Innovation<br />
3.1 Growing Opportunities for Biologic Products<br />
3.2 Diversification of Molecular Targets<br />
3.3 Innovative First-in-Class Product Development Remains Attractive<br />
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation<br />
3.5 Sustained Innovation<br />
3.6 MRRSE Research Report Guidance<br />
4 Clinical and Commercial Landscape<br />
4.1 Disease Overview<br />
4.1.1 Chronic and Neuropathic <strong>Pain</strong><br />
4.1.2 Disease Pathophysiology<br />
4.1.3 Diagnosis<br />
4.1.4 <strong>Treatment</strong> Option<br />
4.1.5 <strong>Treatment</strong> Algorithm
Change language